Huateng Pharmaceutical, a global supplier of pharmaceutical intermediates, offers Remdesivir intermediates
2,3,5-Tri-O-benzyl-D-ribonolactone (CAS NO. 55094-52-5) for your requirements of R&D, evaluation, pilots and commercial along with supportive technical package required for evaluation
, also known as GS-5734, is a novel antiviral drug in the class of nucleotide analogs developed by Gilead Sciences. In February 2020 Remdesivir was being studied for experimental treatment of the emergent COVID-19
(novel coronavirus) disease.
Find More Remdesivir Intermediates>>>